Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Addition of Inotuzumab Ozogamicin Pre- and Post-Allogeneic Transplantation
NCT03856216Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) and lymphoma (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Veno-occlusive Disease at 45 days. Started Oct 2019; status: terminated.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT03856216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856216.